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Background The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And
Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in
contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes,
pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF.
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Methods
and results
Adults with HF in New York Heart Association functional class ≥ II, a left ventricular ejection fraction ≤ 40%, an
elevated N-terminal pro-B-type natriuretic peptide concentration and receiving standard treatment were eligible
for DAPA-HF, which is comparing dapagliflozin 10mg once daily to matching placebo. In patients without a history
of diabetes, previously undiagnosed diabetes was defined as a confirmed HbA1c ≥ 6.5%. Among patients without
known or undiagnosed diabetes, pre-diabetes was defined as a HbA1c ≥ 5.7% The remainder of patients, with
a HbA1c < 5.7%, were defined as normoglycaemic. Of the 4744 patients† (mean age 66 years; 23% women)
randomized, 42% had known diabetes and 3% undiagnosed diabetes. Of the remainder, 67% had pre-diabetes and
33% normal HbA1c. Overall, DAPA-HF patients were generally similar to those in recent registries and in relevant
trials and had high levels of background therapy: 94% angiotensin-converting enzyme inhibitor/angiotensin receptor
blocker/angiotensin receptor–neprilysin inhibitor, 96% beta-blocker, and 71% mineralocorticoid receptor antagonist;
26% had a defibrillator. Patients with diabetes had worse HF status, more co-morbidity, and greater renal impairment
but received similar HF therapy. Patients with diabetes received non-insulin hypoglycaemic therapy alone in 49%,
insulin alone in 11%, both in 14%, and none in 26%.
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Conclusions Patients randomized in DAPA-HF were similar to those in other contemporary HF with reduced ejection fraction
(HFrEF) registries and trials. These patients were receiving recommended HFrEF therapy and those with diabetes
were also treated with conventional glucose-lowering therapy. Consequently, DAPA-HF will test the incremental
efficacy and safety of dapagliflozin in HFrEF patients with and without diabetes.
Clinical Trial Registration: ClinicalTrials.gov Identifier NCT03036124
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Introduction
In large clinical trials in patients with type 2 diabetes at high car-
diovascular risk, three different sodium–glucose co-transporter
2 (SGLT2) inhibitors have been shown to reduce the risk of
heart failure (HF) hospitalization.1–3 This beneficial effect was
observed soon after randomization, suggesting a mechanism or
mechanisms of action different from those usually considered
with conventional glucose-lowering therapies.4–8 In addition to a
diuretic-haemodynamic action, effects on myocardial metabolism,
ion channels, fibrosis, adipokines and uric acid have also been
proposed. Many of these actions could also be beneficial in HF
patients without diabetes. The renal protection afforded by SGLT2
inhibitors is also clearly relevant in all patients with HF.9 Conse-
quently, several trials have been designed to prospectively evaluate
the efficacy and safety of SGLT2 inhibitors in patients with estab-
lished HF, both with and without diabetes.10 Here we describe the
baseline characteristics of participants in the Dapagliflozin And Pre-
vention of Adverse-outcomes in Heart Failure (DAPA-HF) trial.
Methods
DAPA-HF is a randomized, double-blind, controlled trial in patients
with chronic HF with reduced ejection fraction (HFrEF), evaluating
the effect of dapagliflozin 10 mg once daily, compared with placebo,
in addition to standard care, on the risk of worsening HF and cardio-
vascular death. The trial is registered as ClinicalTrials.gov Identifier:
NCT03036124 and the design has been published in full.10
Summary of DAPA-HF design
Patients
Men and women aged ≥ 18 years with HF are eligible if they are in
New York Heart Association (NYHA) functional class ≥ II, have a
left ventricular ejection fraction (LVEF) ≤ 40%, are optimally treated
with pharmacological and device therapy for HF, and willing to pro-
vide written informed consent. In addition, patients must have a
N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentra-
tion ≥ 600 pg/mL if not hospitalized for HF within the previous
12months or ≥ 400 pg/mL if hospitalized for HF within the previous
12months. Patients with atrial fibrillation or atrial flutter must have a
level ≥ 900 pg/mL, irrespective of history of HF hospitalization.
Key exclusion criteria include: type 1 diabetes mellitus, symp-
toms of hypotension or systolic blood pressure < 95mmHg, recent
worsening HF or other cardiovascular events or procedures (or
planned procedures), estimated glomerular filtration rate (eGFR)
< 30mL/min/1.73m2 (or rapidly declining renal function), and other
conditions likely to prevent patient participation in the trial or greatly
limit life expectancy. A full list of exclusion criteria is provided in the
design paper.10
Treatment of heart failure
Patients were required to receive standard drug and device therapy
for HFrEF, in accordance with recognized guidelines, including: (i) an
angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor
blocker (ARB), or sacubitril/valsartan, and (ii) a beta-blocker, unless
contraindicated or not tolerated, as well as (iii) a mineralocorticoid
receptor antagonist (MRA), if considered appropriate. ..
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.. Study visits and follow-up
After provision of informed consent, visit 1 started a 14± 7 day
enrolment period during which the trial inclusion and exclusion criteria
were checked, and baseline information was collected (including from
clinical examination and laboratory measurements). Visit 2 was the
randomization visit at which further assessments were conducted and
study drug was dispensed. After randomization, follow-up visits took
place at 14 and 60 days, with a particular focus on assessment of HF
and volume status, adverse events, and checking blood chemistry, and
then at 120, 240, and 360 days and 4 monthly thereafter, as detailed in
the design paper.10
Outcomes
The primary objective is to determine whether dapagliflozin is superior
to placebo, when added to standard care, in reducing the incidence
of a worsening HF episode (hospitalization or the equivalent, i.e.
an urgent HF visit) or cardiovascular death, analysed as time-to-first
event. The first of the secondary outcomes is the composite of
HF hospitalization or cardiovascular death. The additional secondary
outcomes are described in the design paper.10
Statistical considerations
The underlying statistical assumptions in DAPA-HF are described in
the design paper and details of the statistical approach to the analysis
of subgroups, including patients with and without diabetes, are given in
the online supplementary Methods S1.10
Definition of diabetes and pre-diabetes
in DAPA-HF
History of diabetes was provided by investigators. In patients without
a history of diabetes, previously undiagnosed diabetes was defined as
a glycated haemoglobin (HbA1c), measured in a central laboratory, of
≥ 6.5% at both visit 1 and visit 2. Among patients without known or
undiagnosed diabetes, pre-diabetes was defined as a HbA1c ≥ 5.7% at
visit 1 or visit 2. The remainder of patients, with a HbA1c < 5.7% at
both visit 1 and visit 2, were defined as normoglycaemic (euglycaemic).
Comparator registries
Three recent registries encompassing Europe, Asia and the United
States of America (USA) were used for comparison of patients in
DAPA-HF with the so-called ‘real-world’ cohorts.11–17
Comparator trials: summary
of inclusion/exclusion criteria
We compared the baseline characteristics of patients in DAPA-HF with
a number of recent randomized controlled trials.18–21 Two of these
had broad inclusion criteria and are shown in the Results section; two
more had restricted inclusion criteria (e.g. both included only patients
in sinus rhythm and one only those with an ischaemic aetiology) and
are shown in the online supplementary Methods S1.
PARADIGM-HF and ATMOSPHERE
The inclusion and exclusion criteria for the Prospective compari-
son of Angiotensin Receptor neprilysin inhibitors with Angiotensin
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
1404 John J.V. McMurray et al.
Table 1 Baseline characteristics of patients with heart failure and reduced ejection fraction in contemporary
registries and in DAPA-HF
ESC Long-Term
Registry (n = 5460)
ASIAN-HF
(n = 5276)
CHAMP-HF
(n = 3494)
DAPA-HF
(n = 4744)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean age, years 64 60 66 66
Female sex, n (%) 22 22 29 23
Median BMI, kg/m2 28 25 30 27
Mean systolic BP, mmHg 122 118 121 122
Mean heart rate, b.p.m. 73 80 74 72
Mean LVEF, % 29 28 30 31
NYHA class III/IV, % 31 33 32 32
Ischaemic aetiology, % 49 47 40 56
Diabetes, % 32 40 41 42
Arial fibrillation, % 37 18 36 40
Diuretic, % 84 82 61a 93
ACEi/ARB, % 92 75 73b 94b
Beta-blocker, % 93 79 83 96
MRA, % 68 59 33 71
Digoxin, % 24 31 14 19
Ivabradine, % 10 NR 1 5
ARNI, % 0 0 13 11
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; LVEF, left ventricular
ejection fraction; MRA, mineralocorticoid receptor antagonist; NR, not reported; NYHA, New York Heart Association.
aLoop diuretic only.
bIncludes sacubitril/valsartan.
converting enzyme inhibitors to Determine Impact on Global Mor-
tality and morbidity in Heart Failure (PARADIGM-HF) trial and the
Aliskiren Trial of Minimizing OutcomeS in Patients with HEart fail-
uRE (ATMOSPHERE) were almost identical.18,19 Patients were eligible
at screening if: ≥18 years, NYHA class II–IV, LVEF ≤ 35% (changed
from ≤ 40% in PARADIGM-HF by amendment), elevated natriuretic
peptide level, taking an ACE inhibitor or ARB, beta-blocker (unless con-
traindicated or not tolerated) and MRA, if indicated. The natriuretic
peptide eligibility criteria were: BNP ≥150 pg/mL or NT-proBNP
≥ 600 pg/mL; patients hospitalized in the preceding 12months were eli-
gible with a lower level: BNP≥100 pg/mL or NT-proBNP≥ 400 pg/mL.
Exclusion criteria included symptomatic hypotension or systolic blood
pressure < 95mmHg (< 90mmHg in ATMOSPHERE), and eGFR
< 30mL/min/1.73m2 (< 35mL/min/1.73m2 in ATMOSPHERE).
Results
The first patient enrolment visit took place 8 February 2017 and
the first randomization occurred 15 February 2017. Subsequent
recruitment in DAPA-HF was rapid, and randomization was com-
pleted 17 August 2018, with 4744 patients† randomized at 410
sites in 20 countries.
DAPA-HF compared with contemporary
heart failure with reduced ejection
fraction registries
Table 1 shows a comparison of key patient characteristics in three
contemporary HF registries, compared with DAPA-HF. Other
than a somewhat higher percentage of patients with an ischaemic ..
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.. aetiology, patients in DAPA-HF were very similar to those in the
registries, with the exception of the low prevalence of atrial fib-
rillation/flutter in Asian patients, as identified in other studies in
that region of the world. The fraction of patients ≥ 75 years in
the European Society of Cardiology (ESC) Long-Term Registry was
22%, compared with 24% in DAPA-HF. The proportion of patients
≥ 65 years in the Change the Management of Patients with Heart
Failure (CHAMP-HF) registry was 59%, compared with 60% in
DAPA-HF. The mean eGFR in CHAMP-HF was 60mL/min/1.73m2,
which was lower than in DAPA-HF (66mL/min/1.73m2) but the
fraction of patients with an eGFR < 60mL/min/1.73m2 was lower
in CHAMP-HF than in DAPA-HF (26% vs. 41%). The use of con-
ventional, evidence-based, disease-modifying therapy was greater,
overall, in DAPA-HF than in the registries (Table 1 and Figure 1).
The newer treatments, ivabradine and sacubitril/valsartan, were
each used in a small minority of patients, both in the registries
and in DAPA-HF (Table 1). However, the use of sacubitril/valsartan
in DAPA-HF varied greatly by geographical region: 32.3% in North
America, 24.5% in Western Europe, 6.9% in Latin America, 5.4% in
Asia, and 2.7% in Central/Eastern Europe.
DAPA-HF compared with other recent
heart failure with reduced ejection
fraction trials
Table 2 shows a comparison of key patient characteristics in two
recent HFrEF trials (PARADIGM-HF and ATMOSPHERE) with
DAPA-HF. Patients in DAPA-HF were, on average, somewhat older
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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*includes sacubitril/valsartan +required by protocol
Figure 1 Comparison of use of disease-modifying therapy for heart failure with reduced ejection fraction in recent registries, trials and in
DAPA-HF. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.
*Includes sacubitril/valsartan; +required by protocol.
(mean 66 years) than in the other two trials. The percentage of
females was similarly small in all trials. DAPA-HF and ATMO-
SPHERE enrolled more Asians than PARADIGM-HF.
Heart failure characteristics
A larger proportion of patients in DAPA-HF were in NYHA func-
tional class III/IV (32%) than in PARADIGM-HF or ATMOSPHERE
(24% and 28%, respectively). The average Kansas City Cardiomy-
opathy Questionnaire (KCCQ) overall and clinical summary scores
were lower in DAPA-HF, reflecting the NYHA class distributions
in the trials.
Left ventricular ejection fraction was slightly higher in DAPA-HF
than in the other two trials whereas NT-proBNP levels were
broadly similar in all three trials. Heart rate and blood pressure
were similar in each of the trials.
The percentage of patients with prior HF hospitalization was
substantially smaller in DAPA-HF (47%) than in the other two
trials (63% PARADIGM-HF and 60% ATMOSPHERE). In DAPA-HF,
16.4% of patients had been hospitalized for HF in the previous
6 months and 27.3% in the previous year.
The fraction of patients with an ischaemic aetiology was similar
across the three trials.
Past history and co-morbidity
Median body mass index was similar across all three trials. Over-
all, around 30% of patients were obese, with this proportion
somewhat higher in DAPA-HF than in the other trials. The ..
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. percentage of patients with a history of diabetes was higher in
DAPA-HF (42%) than in PARADIGM-HF (34%); the fraction in
ATMOSPHERE was lower because of the exclusion of patients with
diabetes part-way through enrolment.19
The proportion of patients with previous myocardial infarction
and prior coronary revascularization was similar in the three trials
and reflected the prevalence of ischaemic aetiology. The percent-
age of patients with a history of hypertension and prior stroke was
slightly higher in DAPA-HF, compared with the other trials. The
proportion of participants with atrial fibrillation/flutter on their
electrocardiogram was similar across trials. Mean eGFR was low-
est, and the fraction of patients with an eGFR < 60mL/min/1.73m2
was highest, in DAPA-HF (see Discussion section). Overall, 28% of
men and 26% of women in DAPA-HF had anaemia, a slightly higher
proportion than in the other two trials.
Baseline drug and device therapy
Beta-blocker use was higher in DAPA-HF than in any prior trial
(Figure 1), whereas digoxin use was less than in the other trials.
The rate of use of an MRA was very high in DAPA-HF (71%)
compared with PARADIGM-HF (60%) and ATMOSPHERE (37%).
Overall, 10.8% of patients in DAPA-HF were treated with sacubi-
tril/valsartan at baseline and 4.8% with ivabradine. The percentage
treated with ivabradine was 1.0% in ATMOSPHERE and 1.5% in
PARADIGM-HF.
The proportion of patients in DAPA-HF with an implantable
cardioverter-defibrillator (ICD) was larger than in either of the
previous trials.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Baseline characteristics in recent randomized
clinical trials in patients with heart failure and reduced
ejection fraction
PARA-
DIGM-HF
(n = 8442)
ATMOS-
PHERE
(n = 7063)
DAPA-
HF
(n = 4744)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean age, years 64 63 66
Female sex, n (%) 22 22 23
Race (%)
White 66 66 70
Black 5 2 5
Asian 18 25 24
Other 11 7 1
Region (%)
Western Europe 24.4 26.4 11.6
Eastern
Europe/Russia
33.6 27.7 33.8
North America 7.2 2.5 14.3
Latin America 17.0 16.0 17.2
Asia Pacific 17.7 27.4 23.1
HF characteristics
NYHA class, %
I 5 2 0
II 70 69 68
III 24 28 32
IV 1 1 1
Mean KCCQ score
OSS 73 75 68
CSS 73 78 71
Mean LVEF, % 29 28 31
Median NT-proBNP,
pg/mL
All 1615 1198 1437
No AF/F, n 1444 1014 1291
AF/F, n 1955 1652 1945
History of HF
hospitalization, %
63 60 47
Ischaemic aetiology, % 60 56 56
Mean blood pressure,
mmHg
Systolic 121 124 122
Diastolic 74 75 74
Mean heart rate,
b.p.m.
72 72 72
Medical history
and co-morbidity
Median BMI, kg/m2 28 27 27
Obese, % 32 27 35
Diabetes, % 34 28 42
Hypertension, % 71 62 74
MI, % 43 41 44
PCI, % 21 20 34
CABG, % 15 14 17
Stroke, % 9 7 10
Atrial fibrillation/
flutter, %
History 37 34 40
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.. Table 2 Continued
PARA-
DIGM-HF
(n = 8442)
ATMOS-
PHERE
(n = 7063)
DAPA-
HF
(n = 4744)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ECG 25 23 24
Mean eGFR,
mL/min/1.73m2
68 74 66
eGFR < 60mL/
min/1.73m2, %
37 27 41
Mean haemoglobin, g/L 140 138 136
Anaemia, %
Men 21 22 28
Women 18 24 26
Treatment (%)
Diuretic 80 80 93
ACEi 78 100 56
ARB 23 0 28
ACEi or ARB 100 100 94a
𝛽-blocker 93 92 96
MRA 60 37 71
Digitalis glycoside 30 32 19
Ivabradine 2 1 5
CRT 7 6 7
ICD 15 15 26
ACEi, angiotensin-converting enzyme inhibitor; AF/F, atrial fibrillation/flutter;
ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary
artery bypass grafting; CRT, cardiac resynchronization therapy; CSS, clinical
summary score; ECG, electrocardiogram; eGFR, estimated glomerular filtration
rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; KCCQ, Kansas
City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; MRA, mineralocorticoid receptor antagonist; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association;
OSS, overall summary score; PCI, percutaneous coronary intervention.
aIncludes 10.8% taking sacubitril/valsartan.
A comparison of DAPA-HF with the Systolic Heart Failure Treat-
mentWith the If Inhibitor Ivabradine Trial (SHIFT) and the Study to
Assess the Effectiveness and Safety of Rivaroxaban in Reducing the
Risk of Death, Myocardial Infarction or Stroke in Participants with
Heart Failure and Coronary Artery Disease Following an Episode
of Decompensated Heart Failure (COMMANDER-HF) is shown in
the online supplementary Table S1.
Comparison of patients with and without
diabetes
Of all patients randomized, 1983 (42%) had a pre-existing diagnosis
of diabetes and 154 a HbA1c in the diabetes range at visit 1 and
visit 2, i.e. the total number with known or undiagnosed diabetes
was 2137 (45%). The baseline characteristics of these two groups
are shown in Table 3 and discussed further below.
Of the 2607 patients without diabetes, 1750 had pre-diabetes
(67% of those without diabetes and 37% of all randomized partici-
pants) and 857 a normal HbA1c (33% and 18%, respectively). The
baseline characteristics of these two groups, as well as patients with
diabetes, are shown in the online supplementary Table S2.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Baseline characteristics of patients in
DAPA-HF according to glycaemic status
No diabetes
(n = 2607)
Diabetes
(n = 2137)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean age, years 66.2 66.6
> 65 years, % 58 57
> 75 years, % 23 19
Female sex, n (%) 24 22
Race (%)
White 71 70
Black 3.8 6.0
Asian 24 23
Other 1.5 1.5
HF characteristics
NYHA class, %
II 71 64
III 29 35
IV 0.8 1.0
Mean KCCQ score
OSS 69.7 66.4
CSS 72.7 69.2
Mean LVEF, % 31 31
LVEF range 36–40, % 28 31
Median NT-proBNP, pg/mL
All 1413 1484
No AF/F 1265 1325
AF/F 1876 2046
History of HF hospitalization, % 46 49
≤ 6 months 15 18
≤12months 27 28
Ischaemic aetiology, % 51 62
Mean blood pressure, mmHg
Systolic 121 123
Diastolic 73 74
Systolic blood pressure
≥130mmHg, % 26 34
≥140mmHg, % 10.9 15.1
Mean ECG QRS duration, ms 123 121
≥130ms,% 36 33
≥150ms, % 24 20
Mean heart rate, b.p.m. 71 72
No AF/F, b.p.m. 69 71
AF/F, b.p.m. 76 76
Medical history and co-morbidity
Median BMI, kg/m2 26 29
Obese, % 28 44
Hypertension, % 68 82
MI, % 40 49
PCI, % 30 39
CABG, % 14 20
Stroke, % 9 11
Atrial fibrillation/flutter, %
History 41 38
ECG 24 24
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. Table 3 Continued
No diabetes
(n = 2607)
Diabetes
(n = 2137)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sleep apnoea, % 4.4 7.2
Foot ulcer, % 0.5 2.1
Amputation, % 0.7 1.9
Neuropathy, % 1.5 9.3
Mean eGFR, mL/min/1.73m2 67.8 63.3
eGFR < 60mL/min/1.73m2, % 36.2 46.0
Mean HbA1c, % 5.8 7.4
Mean BUN, mmol/L 7.8 9.0
Serum potassium, mmol/L 4.5 4.6
Haemoglobin, g/L 137 134
Anaemia, %
Men 23.4 33.6
Women 25.2 28.0
HF treatment (%)
Diuretic 92 95
ACEi 57 55
ARB 26 29
ARNI 10.7 10.9
𝛽-blocker 95 97
MRA 70 71
Digitalis glycoside 17.5 19.8
CRT 7.8 7.1
ICD 25.5 27.0
Diabetes treatment (%)
Biguanidea 0.4 47
Sulfonylurea 0 20
DPP-4 inhibitor 0 14
𝛼-glucosidase inhibitor 0 4.2
GLP-1 receptor agonist 0 1.0
Insulin 0 25
Insulin only 0 11
Insulin with other therapy 0 14
ACEi, angiotensin-converting enzyme inhibitor; AF/F, atrial fibrillation/flutter;
ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin
inhibitor; BMI, body mass index; BUN, blood urea nitrogen; CABG, coro-
nary artery bypass grafting; CRT, cardiac resynchronization therapy; CSS, clini-
cal summary score; DPP, dipeptidyl peptidase; ECG, electrocardiogram; eGFR,
estimated glomerular filtration rate; GLP, glucagon-like peptide; HbA1c, gly-
cated haemoglobin; HF, heart failure; ICD, implantable cardioverter-defibrillator;
KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejec-
tion fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antago-
nist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York
Heart Association; OSS, overall summary score; PCI, percutaneous coronary
intervention.
aMetformin in all cases.
Patients with pre-diabetes were older than individuals with a
normal HbA1c but were otherwise more similar to euglycaemic
patients than patients with type 2 diabetes.
Heart failure characteristics
Patients with pre-diabetes and diabetes had worse KCCQ scores
than those without diabetes and the NYHA class distribution was
worse in patients with diabetes.
The proportion of patients with an ischaemic aetiology was
higher in those with diabetes (62%) than in those without. Mean
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LVEF was similar in both groups but NT-proBNP was higher in
patients with diabetes. Heart rate was similar in the two groups
but blood pressure (and the percentage with an elevated blood
pressure) was highest in patients with diabetes.
The proportion of patients with a prior HF hospitalization did
not differ greatly between the groups.
Past history and co-morbidity
Median body mass index and the fraction of obese patients
increased significantly between those with and without diabetes
(44% and 28%, respectively).
The proportion of patients with a history of myocardial
infarction and coronary revascularization was higher in patients
with diabetes, in keeping with the fraction of patients with an
ischaemic aetiology. The percentage of participants with a history
of hypertension differed in a similar way, consistent with baseline
blood pressure. Investigator-reported co-morbidities collected in
DAPA-HF, additional to those collected in the other trials, were
foot ulcer, amputation, neuropathy and sleep apnoea. Each of
those was uncommon but more frequent in patients with a history
of diabetes, although were also reported in a few patients without
diabetes.
Mean eGFR was lower, and the proportion of patients with an
eGFR < 60mL/min/1.73m2 higher, in those with diabetes com-
pared to no diabetes, with 46% of patients in the former group
categorized as having chronic kidney disease. The percentage of
patients with anaemia was also highest among those with diabetes
(33.6% of men and 28.0% of women).
Baseline drug and device therapy for heart failure
A similar fraction of patients in each group was treated with a
renin–angiotensin system blocker, beta-blocker, a MRA and devices
[ICD and cardiac resynchronization therapy (CRT)]. The highest
rate of use of digoxin was in the diabetes group.
Baseline therapy for diabetes
In patients with a pre-existing diagnosis of diabetes (n = 1983),
27.0% were treated with insulin (11.8% with only insulin), 50.8%
with a biguanide, 21.7% with a sulfonylurea, 15.4% with a dipeptidyl
peptidase-4 (DPP-4) inhibitor, 4.5% with an alpha glucosidase
inhibitor, 1.1% with a glucagon-like peptide 1 receptor agonist,
and 0.6% with a thiazolidinedione. The proportion of patients
with known diabetes receiving no glucose-lowering treatment was
20.3%. These percentages were slightly different when the total of
patients with known or unknown diabetes (n = 2137) was used as
the denominator (Table 3).
Discussion
DAPA-HF is one of the two large mortality/morbidity trials
evaluating the effects of a SGLT2 inhibitor in outpatients with
HFrEF.10,22 Both DAPA-HF and the EMPagliflozin outcomE tRial in
patients with chrOnic heaRt Failure with Reduced ejection fraction
(EMPEROR-Reduced) trial allow inclusion of patients without as ..
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.. well as with a history of diabetes.10,22 Consistent with this, the
majority (58%) of patients enrolled in DAPA-HF did not have
known diabetes. The proportion with an existing diagnosis of dia-
betes (42%) was similar to that in contemporary registries but
somewhat larger than in the comparator HFrEF trials.11–17,21 The
patients randomized in DAPA-HF were also broadly similar, in
other respects, to those in the recent registries, although, as has
been recognized previously, atrial fibrillation was less frequent in
Asian patients.11–17 Patients in DAPA-HF were also generally similar
to those in the comparator trials with globally diverse enrolment
(particularly PARADIGM-HF and ATMOSPHERE), taking account
of specific inclusion and exclusion criteria and other issues such as
the cessation of randomization of patients with diabetes part-way
through recruitment in ATMOSPHERE.23 One of the few excep-
tions included the fraction obese, which was larger in DAPA-HF,
in keeping with higher prevalence of diabetes and hypertension in
DAPA-HF. The worse kidney function in DAPA-HF probably also
reflects the slightly older age and high prevalence of diabetes and
hypertension in the current trial, as well as the very high rate of
use of renin–angiotensin–aldosterone system blockers, including
an MRA in 71% of patients (see below). The high frequency of
renal dysfunction in COMMANDER-HF is also consistent with this
interpretation.21
Three other differences of note include: (i) the low rate of
use of digoxin, (ii) the higher use of devices, especially an ICD
than in the other trials, and (iii) the lower proportion (47%) of
patients with a prior HF hospitalization. The low use of digoxin
probably reflects a historical decline related to the availability of
alternative therapeutic options, as well as safety concerns about
digoxin; digoxin use was also low in the CHAMP-HF registry.13,14,24
The higher rate of ICD/CRT-D use in DAPA-HF, compared with
PARADIGM-HF, however seems to be wholly accounted for by the
regional distribution of patients in the two trials, and reflects the
higher rate of implantation of these devices in North America and
Europe, compared with other geographical areas. This variation
likely reflects economic restrictions and is similar to that seen for
new (and more costly) pharmacological therapies (see below).
The percentage of patients in the ESC Long-Term Registry with a
history of HF hospitalization was also 47%. The fraction with such
an admission in the prior 12months was 27% in DAPA-HF and
38% in CHAMP-HF. These lower rates than historically reported
may reflect changing practice aimed at avoiding admission and, also,
the effectiveness of modern HF therapies used in combination.25
Our finding that approximately 70% of patients without a prior
diagnosis of diabetes had previously undiagnosed diabetes or
pre-diabetes is in keeping with the only other analyses of this type
we know of from PARADIGM-HF and GISSI-HF, although in these
other reports only a single baseline HbA1c was available.26,27 Part
of the hypothesis for using SGLT2 inhibitors in HFrEF patients not
known to have diabetes is that glucose lowering may also be ben-
eficial in patients with pre-diabetes and may delay or prevent the
development of diabetes, and the present findings show that we
will be able to test this theory in DAPA-HF.10
Comparison of patients with a normal HbA1c, pre-diabetes
and any diabetes (existing diagnosis and undiagnosed combined)
is therefore of some interest. Patients with diabetes were older
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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than those with a normal HbA1c and had worse symptoms and
quality of life, despite a similar LVEF and proportion with a history
of HF hospitalization. Patients with diabetes did, however, have a
higher NT-proBNP level and more often had an ischaemic aeti-
ology (and other manifestations of coronary artery disease) than
participants with a normal HbA1c. Patients with pre-diabetes gen-
erally exhibited findings intermediate between these two ends of
the spectrum, illustrating that ‘non-diabetic’ patients in prior trials
are a heterogeneous group, with clearly worse HF status in patients
with dysglycaemia compared to those who are euglycaemic.
Certain co-morbidities, however, were distinctly more com-
mon just in those with diabetes, particular obesity, hypertension
(whether as history or as determined by measurement of blood
pressure), sleep apnoea (which might relate to obesity, if predom-
inantly obstructive in type), renal impairment, anaemia and neu-
ropathy. The triad of diabetes, chronic kidney disease and anaemia
(sometimes referred to as the ‘cardiorenal–anaemia syndrome’) is
associated with particularly poor outcomes in HF.28
A particularly important consideration in any trial evaluating a
new, incremental, therapy is the adequacy of background treat-
ment. In DAPA-HF, rates of use of conventional therapy were high,
comparing favourably with other trials and, especially, ‘real-world’
cohorts. The ESC Long-Term Registry reported use of an ACE
inhibitor or ARB in 92%, a beta-blocker in 93% and an MRA in
68% of 4792 patients with HFrEF.11,12 However, in the recent
CHAMP-HF registry from the USA, these rates were much lower:
73%, 83% and 33%, respectively, despite the patients having a similar
mean age and LVEF, and lower percentage of patients with chronic
kidney disease, than those in DAPA-HF.13,14,28 This may explain
the higher median baseline NT-proBNP level in CHAMP-HF (2013
vs. 1437 pg/mL), lower KCCQ overall summary score (62 vs. 68)
and smaller fraction with an eGFR < 60mL/min/1.73m2 (26% vs.
41%), compared with DAPA-HF. In CHAMP-HF, more comprehen-
sive therapy was associated with much lower NT-proBNP levels
and lower eGFR.13,14,28
Looking at novel HFrEF therapies, only 11% of patients in
DAPA-HF were treated with the angiotensin receptor–neprilysin
inhibitor combination, sacubitril/valsartan, a finding consistent with
the 13% receiving this therapy in the recent CHAMP-HF registry
mentioned above.13,14,29 However, the percentage treated with
sacubitril/valsartan varied widely in DAPA-HF, from 32% in North
America and 25% in Western Europe to 7% or less in other
regions, perhaps reflecting different economic circumstances and
health service provision. Ivabradine was also little used in recent
trials and registries. Sacubitril/valsartan is of particular interest in
patients with dysglycaemia as neprilysin is reported to metabolise
glucagon-like peptide-1 and neprilysin inhibition to reduce HbA1c
and need for insulin in HFrEF patients with diabetes.30
We found identical rates of use of all key HFrEF therapies in
patients with and without diabetes. Indeed, although the propor-
tion of diabetes patients in DAPA-HF with chronic kidney dis-
ease was striking (46% of patients with diabetes), the use of ACE
inhibitors, ARBs and MRAs was as high in the other patient sub-
groups in the trial. These findings are consistent with reports
from PARADIGM-HF, SHIFT and the ESC Long-Term Registry
and encouraging, given prior observations of underuse of these ..
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.. life-saving treatments because of misplaced concerns about their
use in patients with renal dysfunction.26,31,32 Another interesting
comparison is a very large registry which included US (n = 28 877)
and Asian (n = 2235) patients with both HFrEF and diabetes.33
There was a gradient in use of treatment from low-income Asian
countries, through high-income Asian countries to the USA: ACE
inhibitor or ARB use 68.5% to 76.6% and beta-blocker use 68.3%
to 90.5%; MRA use was not reported.
Regarding anti-hyperglycaemic therapy, most patients with a
history of type 2 diabetes in DAPA-HF were treated with oral
glucose-lowering therapy (oral therapy only in 53%), insulin (insulin
alone in 12%) or both (15%), with 20% of patients receiving no
glucose-lowering therapy, findings consistent with other studies.
Specifically, in the ESC Long-Term Registry, 28% of patients were
not receiving glucose-lowering therapy and in the US/Asian cohort
study mentioned earlier, 30–40% of patients with HFrEF were not
receiving glucose-lowering treatment, similar to the percentage in
PARADIGM-HF.26,32 About a fifth of patients with type 2 diabetes
were not treated with pharmacological glucose-lowering therapy in
other registries, diabetes trials and HF studies.34–36 There are few
detailed descriptions of the classes of oral glucose-lowering thera-
pies prescribed for patients with HFrEF but in the reports available,
the pattern is similar to what we observed in DAPA-HF – with
metformin, sulfonylureas and DPP-4 inhibitors accounting for the
large majority of these. However, what was different among the
studies was the fraction of patients treated with insulin, which var-
ied in the prior reports from 44% in the USA to 24% in Asia; in
PARADIGM-HF the proportion was 25% and in SHIFT 32%. This
pattern of greater use of insulin in North America, to treat type 2
diabetes, has been reported previously.26,30–33,37
Consequently, DAPA-HF will test the potential incremental effi-
cacy (and safety) of dapagliflozin, not only in addition to compre-
hensive disease-modifying pharmacotherapy for HFrEF but also in
addition to insulin, conventional non-insulin anti-hyperglycaemic
therapies and dietary management of type 2 diabetes.38
In summary, DAPA-HF has enrolled patients with and without
diabetes who have persisting symptoms, a reduced LVEF and an
elevated NT-proBNP level, who are similar to those enrolled in
contemporary HFrEF registries and randomized in other recent
HFrEF trials. The high prevalence of obesity, type 2 diabetes
and pre-diabetes, and chronic kidney disease in these patients
emphasises the ‘cardiometabolic’ profile of HFrEF and the potential
for SGLT2 inhibition to improve outcomes through glycaemic, renal
and other mechanisms.
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